Grifols (GRFS) Shares Outstanding (Weighted Average) (2010 - 2025)

Grifols (GRFS) reported Shares Outstanding (Weighted Average) of $792.1 million for Q4 2025, up 9.07% on a YoY basis from $726.3 million in Q4 2024, and up 9.07% quarter-over-quarter from $726.3 million in Q4 2024.

Grifols (GRFS) Shares Outstanding (Weighted Average) (2010 - 2025) Analysis & Trends

Grifols has reported Shares Outstanding (Weighted Average) for 16 years, with the latest figure at $792.1 million in Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 9.07% year-over-year to $792.1 million; the trailing twelve-month figure through Dec 2025 stood at $792.1 million (up 9.07% YoY), and the FY2025 full-year result was $792.1 million, up 16.55% from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 stood at $792.1 million, up from $726.3 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $792.1 million in Q4 2025, with the low at $122.0 million in Q4 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $630.3 million across 5 years, with a median of $731.4 million in 2023.
  • Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) slumped 84.35% — and 2023, when it surged 499.36%.
  • Grifols' Shares Outstanding (Weighted Average) stood at $779.7 million in 2021, then tumbled by 84.35% to $122.0 million in 2022, then surged by 499.36% to $731.4 million in 2023, then decreased by 0.7% to $726.3 million in 2024, then increased by 9.07% to $792.1 million in 2025.
  • The last three Shares Outstanding (Weighted Average) figures came in at $792.1 million (Q4 2025), $726.3 million (Q4 2024), and $731.4 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Weighted Avg.) (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 1,818,692.66 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 894.50 Mn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 2.41 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 1.77 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 2.47 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 540.00 Mn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 1.24 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 5.69 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 2.04 Bn
10 Grifols 6.05 Bn 5.09 Bn - 792.15 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 792.15 Mn
Dec 31, 2024 726.29 Mn
Dec 31, 2023 731.38 Mn
Dec 31, 2022 122.03 Mn
Dec 31, 2021 779.68 Mn
Dec 31, 2020 817.33 Mn
Sep 30, 2020 139,706.71
Mar 31, 2020 132,035.52
Dec 31, 2019 758.35 Mn
Sep 30, 2019 133,086.96
Dec 31, 2018 781.52 Mn
Sep 30, 2018 139,114.90
Jun 30, 2018 142,740.73
Mar 31, 2018 146,937.44
Dec 31, 2017 805.60 Mn
Jun 30, 2017 450.82
Dec 31, 2016 460.10 Mn
Sep 30, 2016 658.55
Jun 30, 2016 440.65
Dec 31, 2015 749.25 Mn